Could Subjective Cognitive Complaints Give the Facts of Objective Cognitive Impairments in Non-Central Nervous System Cancer? A Systematic Review.

Brain BehavSep 1, 2026
Clinical ResearchOncology (Medical)NeurologyOpen access

Chieh-Ning Li, Nai-Wen Guo, Bei-Yi Su

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the relationship between subjective cognitive complaints (SCCs) and objective neuropsychological assessments in non-central nervous system cancer patients. Analyzing 16 studies with 2093 participants, the review found low but significant correlations between SCCs and objective measures, with 57.18% of variance attributed to within-study factors. The findings suggest that SCCs may predict neuropsychological functions under specific conditions.

Key findings

  • Correlations between SCCs and objective neuropsychological assessments were low but significant.
  • 57.18% of the variance in correlations was attributed to within-study variance.
  • Increased female ratio led to inconsistent correlations with executive function but consistent with attention and memory.

Why it matters

Understanding the relationship between subjective and objective cognitive assessments can enhance clinical evaluations in cancer patients, guiding more tailored interventions and support strategies.

Source

PubMed · PMID 42670223Free full text on PubMed Central

Published in Brain Behav. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.